mr. H.I. (Renske) ten Kieft

mr. H.I. (Renske) ten Kieft

Assistant Professor
mr. H.I. (Renske) ten Kieft
  • Department of Public Health, Healthcare Innovation & Evaluation and Medical Humanities (PHM)



Renske ten Ham is an assistant professor at the UMC Utrecht in the Netherlands and specializes in health economics & health technology assessment (HTA) of gene and cell-based therapies. Trained as a pharmacist and with an MSc in HTA, she holds a PhD in Drug Innovation titled: “Development, market authorization and market access of gene- and cell-based therapies”.

Over the years Renske conducted research at the University of California, San Francisco (UCSF), spend time at the Dutch Medicines Evaluation Board (CBG-MEB) and National Healthcare Institute (Zorginstituut Nederland) and collaborated with several research groups, amongst which the Center of Health Economics at the University of York. 

At the Julius Center Renske strives to increase translation of (academic) gene and cell-based therapies towards implementation in healthcare services to facilitate patient access. In doing so her research focusses on payment models, development cost, (early) economic evaluations and business models. She aims to contribute to better understanding of the fit between gene and cell-based therapies and existing development frameworks. This is not only relevant for these transformative therapies but also for future biomedical innovations.

Side Activities


  • Chair-elect -  ISPOR Special Interest Group Precision Medicine and Advanced Therapies
  • Member - Young Science in Transition
  • Member - The Professional Society for Health Economics and Outcomes Research (ISPOR) 
  • Member - Dutch Association of Medical Technology Assessment (NVTAG)
  • Member - Dutch Association for Health Economics (VGE)


  • Member - Scientific Program Planning Committee PDA Advanced Therapy Medicinal Products Conference to be held 22-23 June 2022 in Brussels, Belgium
  • Board member NVTAG (Nederlandse Vereniging voor Technology Assessment in de Gezondheidszorg) [2017 - 2020]
  • President young-NVTAG (Nederlandse Vereniging voor Technology Assessment in de Gezondheidszorg [2017 - 2020]
  • Founder & president ISPOR (International Society for Pharmacoeconomics and Outcomes Research) Student Chapter at Utrecht University. [2014 - 2016]

Fellowship and Awards

Greiner Award 2020&2021

  • Award for the best thesis defended in 2020&2021
  • By Dutch Association of Gene & Cell Therapy (NVGCT)

Publication featured as Trends Editors Pick 2020

  • Journal: Trends in Pharmacological Sciences
  • Awarded publication: Development and Regulation of Gene and Cell-Based Therapies in Europe: A Quantification and Reflection.

Publication featured as  Editors Pick 2020

  • Journal: Value in Health
  • Awarded publication: A Review of Methodological Considerations for Economic Evaluations of Gene Therapies and Their Application in Literature.

Best Scientific Poster 2019

  • Conference: TOPRA Conference 2019
  • Awarded poster: Challenges in Advanced Therapy Medicinal Product Development

Research Output (6)

Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A

Ten Ham Renske M T, Walker Sikon M, Soares Marta O, Frederix Geert W J, Leebeek Frank W G, Fischer Kathelijn, Coppens Michiel, Palmer Stephen J 28 Feb 2022, In: HemaSphere. 6 , p. 1-11

Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients

ten Ham Renske M.T., van Nuland Merel, Vreman Rick A., de Graaf Laurens G., Rosing Hilde, Bergman André M., Huitema Alwin D.R., Beijnen Jos H., Hövels Anke M. Jan 2021, In: Value in Health. 24 , p. 121-128 8 p.

The Relative Impact of Urinary and Sexual Function vs Bother on Health Utility for Men With Prostate Cancer

Jeong Chang Wook, Herlemann Annika, Cowan Janet E., Broering Jeanette M., ten Ham Renske M. T., Wilson Leslie S., Carroll Peter R., Cooperberg Matthew R. 2021, 4

A Review of Methodological Considerations for Economic Evaluations of Gene Therapies and Their Application in Literature

ten Ham RMT, Klungel Olaf, Leufkens H.G.M., Frederix GWJ Sep 2020, In: Value in Health. 23 , p. 1268-1280 13 p.

What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings

Ham RMT, Hovels Anke M., Hoekman J., Frederix GW, Leufkens H.G.M., Klungel Olaf, Jedema I., Nikolic T., van Pel M., Zwaginga J.J., de Goede A., Schreibelt Gerty, de Vries I Jolanda M, Dolstra Harry, Ovelgonne H, Meij P, Mountford J.C., Turner M.L, Hoefnagel MHN Jul 2020, In: Cytotherapy. 22 , p. 388-397 10 p.

Development and Regulation of Gene and Cell-Based Therapies in Europe: A Quantification and Reflection

ten Ham RM, Hovels Anke, Klungel Olaf, Broekmans André, Hoekman Jarno Feb 2020, In: Trends in Pharmacological Sciences. 41 , p. 67-71 5 p.

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet